This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Labor Day is almost here, which means the sprint to the end of 2024 is upon us.
If you’re reading this late-August newsletter from the beach, the pool, or the mountains, I thank you for it. But when you’re done, put down your phone.
The asset is currently being investigated as a potential treatment for metastatic pancreatic ductal adenocarcinoma. MattL_Images/Shutterstock. Taiho Pharmaceutical has exercised an option for an exclusive
The REDUCE-AMI trial found that long-term beta-blocker therapy does not reduce mortality risk in acute myocardial infarction patients with preserved left ventricular ejection fraction compared
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Zimvie secured 510(k) clearance for
